stimulon


Also found in: Encyclopedia, Wikipedia.

stimulon

(stĭm′ū-lŏn″)
A cluster of genes whose transcription is modified by a single stimulus.
Medical Dictionary, © 2009 Farlex and Partners
References in periodicals archive ?
Agenus' QS-21 Stimulon is a proprietary adjuvant, currently incorporated as part of Glaxo Smith Kline's (GSK's) highly efficacious Shingrix vaccine.
"Our proprietary position is further strengthened with the European Patent Office's decision to uphold this key European patent, which together with our existing United States patents, provides broad protection for our Stimulon technology," said Alison Taunton-Rigby, PhD, president and chief executive officer of Aquila.
Aquila's corporate partners, which include SmithKline Beecham (Philadelphia, PA), Pasteur Merieux Connaught, Wyeth Lederle (Radner, PA), Vaxgen, Bristol-Myers Squibb (Progenics Pharmaceuticals) and Virbac S.A., have licensed QS-21 and other Stimulon adjuvants for use in products targeted at a variety of human diseases.
The adjuvant, which goes by the designation QS-21, or its trade name Stimulon, was isolated by the company's scientists from compounds called saponins in the bark of the Peruvian tree Quillaja saponaria.
M2 EQUITYBITES-October 26, 2017-Agenus' Shingrix with QS-21 Stimulon vaccine recommended for immunisation for prevention of shingles by ACIP
M2 PHARMA-October 26, 2017-Agenus' Shingrix with QS-21 Stimulon vaccine recommended for immunisation for prevention of shingles by ACIP
The United States Food and Drug Administration (FDA) has granted marketing authorisation to UK-based GlaxoSmithKline's herpes zoster vaccine, SHINGRIX, containing Agenus' proprietary immune adjuvant QS-21 Stimulon, it was reported on Friday.
- The US Food and Drug Administration has granted marketing authorization to Shingrix, GlaxoSmithKline's herpes zoster vaccine containing Lexington, Massachusetts-based immuno-oncology company Agenus Inc.'s (NASDAQ: AGEN) proprietary immune adjuvant QS-21 Stimulon, the company said.
Agenus (AGEN) has announced that the Food and Drug Administration granted marketing authorization to GlaxoSmithKline's (GSK) herpes zoster vaccine, SHINGRIX, containing Agenus' proprietary immune adjuvant QS-21 Stimulon. SHINGRIX is indicated for prevention of herpes zoster - also known as shingles - in adults aged 50 years and older.
RTS,S reportedly contains Agenus' QS-21 Stimulon adjuvant, which is part of GSK's AS01 proprietary adjuvant system.
It includes Agenus's QS-21 Stimulon adjuvant, a component of GSK's novel adjuvant system AS15.
19 October 2011 - Agenus Inc (NASDAQ:AGEN), a specialist in the development of therapeutic vaccines for cancer and infectious diseases, announced on Tuesday positive results of a Phase III trial of GlaxoSmithKline (LONGSK) Biologicals' RTS,S malaria vaccine candidate, which contains Agenus's QS-21 Stimulon adjuvant.